Oculis Holding AG (OCS) Change in Accured Expenses (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Change in Accured Expenses of $1.1 million for Q1 2026, up 436.05% year-over-year from $209877.6 in Q1 2025, and up 514.37% quarter-over-quarter from -$271503.8 in Q4 2025.
Oculis Holding AG (OCS) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Oculis Holding AG's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 436.05% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at -$832893.9 (down 105.56% YoY), while the FY2025 annual figure was -$2.3 million, down 121.96% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $1.1 million, up from -$271503.8 in the prior quarter.
- The five-year high for Change in Accured Expenses was $6.7 million in Q2 2024, with the low at -$5.8 million in Q1 2023.
- The 5-year median for Change in Accured Expenses is $890610.0 (2023), against an average of $275292.4.
- The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses tumbled 142.73% in 2025, then surged 436.05% in 2026.
- Oculis Holding AG's Change in Accured Expenses stood at $2.5 million in 2022, then sank by 64.62% to $890610.0 in 2023, then soared by 312.08% to $3.7 million in 2024, then slumped by 107.4% to -$271503.8 in 2025, then jumped by 514.37% to $1.1 million in 2026.
- Business Quant data shows OCS's Change in Accured Expenses at $1.1 million in Q1 2026, -$271503.8 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.13 Mn |
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | -271,503.84 |
| Dec 31, 2025 | -271,503.84 |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | -2.86 Mn |
| Jun 30, 2025 | -2.86 Mn |
| Mar 31, 2025 | -334,787.41 |
| Mar 31, 2025 | -334,787.41 |
| Dec 31, 2024 | 3.67 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Sep 30, 2024 | 4.95 Mn |
| Jun 30, 2024 | 6.69 Mn |
| Jun 30, 2024 | 6.69 Mn |
| Mar 31, 2024 | -4.76 Mn |
| Mar 31, 2024 | -4.76 Mn |
| Dec 31, 2023 | 890,610.03 |
| Dec 31, 2023 | 890,610.03 |